- Home
- TDF vs PYXS Comparison
TDF vs PYXS Comparison
Compare TDF & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TDF | PYXS |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.8M | 243.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TDF | PYXS |
|---|---|---|
| Price | $11.22 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 79.2K | ★ 633.1K |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.15 | $0.83 |
| 52 Week High | $10.62 | $5.55 |
Technical Indicators
Market Signals| Indicator | TDF | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 22.73 |
| Support Level | $10.95 | $4.10 |
| Resistance Level | $11.44 | $4.58 |
| Average True Range (ATR) | 0.16 | 0.42 |
| MACD | -0.00 | -0.27 |
| Stochastic Oscillator | 51.55 | 5.48 |
Price Performance
Historical ComparisonAbout TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.